Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration

Journal of Clinical Psychopharmacology

Volumn 27, Issue 1, 2007, Pages 15-21

  Morrens, Manuel ^a   Wezenberg, Elke ^b,c   Verkes, Robert Jan ^c   Hulstijn, Wouter ^a,b   Ruigt, Ge S F ^d   Sabbe, Bernard G C ^a,e  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NV ORGANON   (Netherlands)

^e St Norbertus Hospital   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; PAROXETINE; PLACEBO;

ACUTE DRUG ADMINISTRATION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPTH PERCEPTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY DISORDER; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR DISORDER; PSYCHOMOTOR PERFORMANCE; SACCADIC EYE MOVEMENT; SENSORIMOTOR FUNCTION; SIDE EFFECT; TASK PERFORMANCE; VELOCITY; VERBAL MEMORY; VISUAL ANALOG SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; HUMANS; MALE; MEMORY; PAROXETINE; PSYCHOMOTOR PERFORMANCE; REFERENCE VALUES;

EID: 33846253966     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e31802dfff0     Document Type: Article

References (52)

1. Nuechterlein KH, Barch DM, Gold JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29-39.
2. Cancro R, Sutton S, Kerr J, et al. Reaction time and prognosis in acute schizophrenia. J Nerv Ment Dis. 1971;153:351-359.
3. Nuechterlein KH. Reaction time and attention in schizophrenia: a critical evaluation of the data and theories. Schizophr Bull. 1977;3:373-428.
4. Zahn TP, Carpenter WT Jr. Effects of short-term outcome and clinical improvement on reaction time in acute schizophrenia. J Psychiatr Res. 1978;14:59-68.
5. Bermanzohn PC, Siris SG. Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Compr Psychiatry. 1992;33:221-232.
6. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
7. Ngan ET, Liddle PF. Reaction time, symptom profiles and course of illness in schizophrenia. Schizophr Res. 2000;46:195-201.
8. Galletly CA, Clark CR, McFarlane AC, et al. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:1329-1338.
9. Heinz A, Knable MB, Coppola R, et al. Psychomotor slowing, negative symptoms and dopamine receptor availability - an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophr Res. 1998;31:19-26.
10. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 1989;98:367-380.
11. Cassens G, Inglis AK, Appelbaum PS, et al. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull. 1990;16:477-499.
12. King DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry. 1990;157:799-811.
13. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry. 2004;55:1013-1022.
14. Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8:457-472.
15. Harris JP, Gelbtuch MH, Phillipson OT. Effects of haloperidol and nomifensine on the visual aftereffects of tilt and movement. Psychopharmacology (Berl). 1986;89:177-182.
16. Williams SA, Wesnes K, Oliver SD, et al. Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. J Clin Psychiatry. 1996;1(57 suppl):7-11.
17. Lynch G, King DJ, Green JF, et al. The effects of haloperidol on visual search, eye movements and psychomotor performance. Psychopharmacology (Berl). 1997;133:233-239.
18. Beuzen JN, Taylor N, Wesnes K, et al. A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. J Psychopharmacol. 1999;13:152-158.
19. Ramaekers JG, Louwerens JW, Muntjewerff ND, et al. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol. 1999;19:209-221.
20. King DJ, Henry G. The effect of neuroleptics on cognitive and psychomotor function. A preliminary study in healthy volunteers. Br J Psychiatry. 1992;160:647-653.
21. Rammsayer TH. Neuropharmacological evidence for different timing mechanisms in humans. Q J Exp Psychol B. 1999;52:273-286.
22. Legangneux E, McEwen J, Wesnes KA, et al. The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. J Psychopharmacol. 2000;14:164-171.
23. Agmo A, Soria P. The duration of the effects of a single administration of dopamine antagonists on ambulatory activity and motor coordination. J Neural Transm. 1999;106:219-227.
24. Weihmuller FB, Hadjiconstantinou M, Bruno JP. Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice. Neurosci Lett. 1988;85:137-142.
25. Simon VM, Parra A, Minarro J, et al. Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice. Eur Neuropsychopharmacol. 2000;10:159-164.
26. van Laar MW, Volkerts ER, Verbaten MN, et al. Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory. Psychopharmacology (Berl). 2002;162:351-363.
27. Furlan PM, Kallan MJ, Ten Have T, et al. Cognitive and psychomotor effects of paroxetine and sertraline on healthy elderly volunteers. Am J Geriatr Psychiatry. 2001;9:429-438.
28. Loubinoux I, Pariente J, Boulanouar K, et al. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage. 2002;15:26-36.
29. Loubinoux I, Tombari D, Pariente J, et al. Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. Neuroimage. 2005;27:299-313.
30. Sabbe B, van Hoof J, Hulstijn W, et al. Changes in fine motor retardation in depressed patients treated with fluoxetine. J Affect Disord. 1996;40:149-157.
31. Johnson AM. An overview of the animal pharmacology of paroxetine. Acta Psychiatr Scand Suppl. 1989;350:14-20.
32. Nelson HE, Pantelis C, Carruthers K, et al. Cognitive functioning and symptomatology in chronic schizophrenia. Psychol Med. 1990;20:357-365.
33. Sullivan EV, Shear PK, Zipursky RB, et al. A deficit profile of executive, memory, and motor functions in schizophrenia. Biol Psychiatry. 1994;36:641-653.
34. Jogems-Kosterman BJ. Psychomotor Slowing and Planning Deficits in Schizophrenia [dissertation]. Nijmegen, The Netherlands: Thesis Katholieke Universiteit Nijmegen; 2004.
35. Morrens M, Hulstijn W, Van Hecke J, et al. Sensorimotor and cognitive slowing in schizophrenia as measured by the symbol digit substitution test. J Psychiatr Res. 2006;40:200-206.
36. Poole JH, Ober BA, Shenaut GK, et al. Independent frontal-system deficits in schizophrenia: cognitive, clinical, and adaptive implications. Psychiatry Res. 1999;85:161-176.
37. Penttila J, Kajander J, Aalto S, et al. Effects of fluoxetine on dopamine D2 receptors in the human brain: a positron emission tomography study with [11C]raclopride. Int J Neuropsychopharmacol. 2004;7:431-439.
38. Middleton FA, Strick PL. Basal ganglia output and cognition: evidence from anatomical, behavioral, and clinical studies. Brain Cogn. 2000;42:183-200.
39. Paquet F, Soucy JP, Stip E. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia. J Neuropsychiatry Clin Neurosci. 2004;16:47-56.
40. Kaplan HI, Sadock BJ. Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. Baltimore, MD: Lippincott Williams & Wilkins; 1998.
41. de Jong WP, Hulstijn W, Kosterman BJM. OASIS software and its application in experimental handwriting research. In: Simner ML, Leedham CG, Thomassen AJWM, eds. Handwriting and Drawing Research: Basic and Applied Issues. Amsterdam, The Netherlands: IOS; 1996.
42. Ammons RB. Acquisition of motor skill: rotary pursuit performance with continuous practice before and after a single rest. J Exp Psychol. 1947;37:393-411.
43. Siegel D. A multivariate study of pursuit rotor skill development. Res Q Exerc Sport. 1990;61:201-205.
44. Wechsler D. Manual for the Wechsler Adult Intelligence Scale - Revised. San Antonio, TX: The Psychological Corporation; 1981.
45. Sabbe B, Hulstijn W, Van Hoof J, et al. Fine motor retardation and depression. J Psychiatr Res. 1996;30:295-306.
46. Pier MP, Hulstijn W, Sabbe BG. Differential patterns of psychomotor functioning in unmedicated melancholic and nonmelancholic depressed patients. J Psychiatr Res. 2004;38:425-435.
47. Vakil E, Blachstein H. Rey auditory-verbal learning test: structure analysis. J Clin Psychol. 1993;49:883-890.
48. Rammsayer TH, Rodewald S, Groh D. Dopamine-antagonistic, anticholinergic, and GABAergic effects on declarative and procedural memory functions. Brain Res Cogn Brain Res. 2000;9:61-71.
49. Banich MT. Motor control. In: Banich MT, ed. Cognitive Neuroscience and Neuropsychology. Boston, MA: Houghton Mifflin Company; 2004:145-183.
50. Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004;161:116-124.
51. Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin Ther. 2005;27:S25-S37.
52. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26:119-136.